Photodynamic therapy with one third dose verteporfin for central serous chorioretinopathy:Prospective intervention trial

Phase 2

• Conditions: Central serous chorioretinopathy

• Registration Number: JPRN-UMIN000002405
• Lead Sponsor: agoya University School of Medicine Department of Ophthalmology

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2009-10-01
• Study Completion: 2011-01-01
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 6

Inclusion Criteria

Not provided

Exclusion Criteria

1. drug allery to verteporfin 2. pregnant or expecting pregnancy 3. porphyria, or hypersensitivity to artificial illumination 4. macular diseases other than CSC 5. others (inappropriate case judged by investigator or subinvestigators)

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
resolution of serous retinal detachment of 4 days, 1 month, 3 months, 6 months, and 1 year after PDT

Secondary Outcome Measures

Name	Time	Method
1)visual acuity 2)thickness of retina and serous retinal detachment at fovea on optical coherence tomography 3)choroidal thickness on optical coherence tomography 4)amplitudes and implicit time of a-wave, b-wave and odcillatory potentials recorded by focal macula electroretinogram 5)visual field 6)fluorescein angiography 7)indocyanine green angiography time of assessment 1)-5) : 4 days, 1 month, 3 months, 6 months, and 1 year after PDT 6),7) : 1 month, 3 months, and 1 year after PDT